-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·04/02/2026 14:12:08
Listen to the news
Canaccord Genuity analyst John Newman initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Price Target of $30.